NCT05736731 - A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression | Biotech Hunter

Enrollment

160

Participants

Timeline

Start Date

April 28, 2023

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions

Solid Tumor, AdultSolid TumorPancreatic CancerPancreatic NeoplasmsPancreas CancerNon Small Cell Lung CancerNon Small Cell Lung Cancer RecurrentNon-Small Cell Squamous Lung CancerNSCLCNSCLC, RecurrentColorectal CancerColorectal NeoplasmsColorectal AdenocarcinomaCRCColorectal Cancer MetastaticCancer

Interventions

BIOLOGICAL

A2B530

Autologous logic-gated Tmod CAR T-cells

DIAGNOSTIC_TEST

xT-Onco with HLA-LOH Assay

An investigational next generation sequencing (NGS) in vitro diagnostic (IVD) medical device

Trial Locations (8)

10016

NYU Langone Medical Center, New York

33136

Moffitt Cancer Center, Tampa

55905

Mayo Clinic Rochester, Rochester

63110

Washington University, St Louis

77030

MD Anderson Cancer Center, Houston

85234

Banner Health, Gilbert

90404

UCLA Medical Center, Los Angeles

92093

University of California San Diego, La Jolla